Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01791829 | A Prospective Cohort Study Evaluating Risk of Local Recurrence Following Breast Conserving Surgery and Endocrine Therapy in Low Risk Luminal A Breast Cancer(LUMINA) | active not recruiting | — | 500 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH |
| 2 |
| Jun 17, 2026 |
| clinicaltrials |
| NCT03362060 | PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer | active not recruiting | Phase 1 | 20 | Massachusetts General HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT03945721 | A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients(UNITY) | active not recruiting | Phase 1 | 21 | Massachusetts General HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04298086 | A Study of the Body's Response to Exercise and a Plant-Based Diet in Overweight Postmenopausal Women With Breast Cancer | active not recruiting | Phase 2 | 43 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04837209 | Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer(NADiR) | active not recruiting | Phase 2 | 32 | Massachusetts General HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07092254 | Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer | active not recruiting | — | 760 | Daiichi SankyoINDUSTRY | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04796220 | Focused Ultrasound and Gemcitabine in Breast Cancer(Breast 54) | active not recruiting | Phase 1 | 32 | Patrick Dillon, MDOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04928261 | Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy | active not recruiting | Phase 4 | 52 | Ottawa Hospital Research InstituteOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT01504789 | Part II: Exercise in Hispanic Breast Cancer Survivors | active not recruiting | N/A | 53 | M.D. Anderson Cancer CenterOTHER | 2 | Jun 15, 2026 | clinicaltrials |
| NCT02513394 | PALbociclib CoLlaborative Adjuvant Study(PALLAS) | active not recruiting | Phase 3 | 5,796 | Alliance Foundation Trials, LLC.OTHER | 21 | Jun 15, 2026 | clinicaltrials |
| NCT02515110 | Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer | active not recruiting | N/A | 137 | Virginia Commonwealth UniversityOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT04457596 | T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial | active not recruiting | Phase 3 | 1,056 | Alliance for Clinical Trials in OncologyOTHER | 3 | Jun 15, 2026 | clinicaltrials |
| NCT05629585 | A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) | active not recruiting | Phase 3 | 1,174 | AstraZenecaINDUSTRY | 17 | Jun 15, 2026 | clinicaltrials |
| NCT00929214 | Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients | active not recruiting | Phase 2 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04421963 | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib(ROSY-O) | active not recruiting | Phase 3 | 185 | AstraZenecaINDUSTRY | 23 | Jun 12, 2026 | clinicaltrials |
| NCT05132296 | Mobile-Health Delivery of Lifestyle Interventions for Women With Breast Cancer | active not recruiting | N/A | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05226663 | A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer | active not recruiting | Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05563220 | Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer(ELEVATE) | active not recruiting | Phase 1 / Phase 2 | 435 | Stemline Therapeutics, Inc.INDUSTRY | 13 | Jun 12, 2026 | clinicaltrials |
| NCT02079662 | The Role of Lifestyle Factors in Breast Cancer-Related Outcomes | active not recruiting | N/A | 110 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT02971748 | Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy | active not recruiting | Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06019988 | Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening and Enhanced Navigation on Care Delivery for Patients With Breast Cancer(Breast_SBDOH) | active not recruiting | N/A | 2,500 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06605261 | Effect of Yoga Program on Quality of Life in Women With Breast Cancer Receiving Endocrine Therapy | active not recruiting | N/A | 64 | Gözde GürOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT03202316 | Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer | active not recruiting | Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT05558722 | Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer(ACNTBC) | active not recruiting | Phase 2 | 31 | Xijing HospitalOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT00393783 | Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity | active not recruiting | Phase 1 | 13 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT02263014 | Psychosocial Outcomes and Contralateral Prophylactic Mastectomy (CPM) | active not recruiting | — | 345 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT02644369 | Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors(INSPIRE) | active not recruiting | Phase 2 | 100 | University Health Network, TorontoOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT02965755 | Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins(IMAGE-II) | active not recruiting | N/A | 200 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT01802346 | Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer | active not recruiting | N/A | 130 | University of Southern CaliforniaOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT01953588 | Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery | active not recruiting | Phase 3 | 1,473 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jun 5, 2026 | clinicaltrials |
| NCT02738866 | Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor | active not recruiting | Phase 2 | 60 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07630558 | Investigation of the Prognostic Value of Patterns of Genomic Alterations or Protein Expression in Patients With Operated Early Breast Cancer | active not recruiting | — | 1,891 | Hellenic Cooperative Oncology GroupOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT00609791 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer | active not recruiting | Phase 2 | 40 | City of Hope Medical CenterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT03737695 | Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer | active not recruiting | — | 300 | Mayo ClinicOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04180579 | Safety of Lower Scalp Cooling Temperature to Prevent Hair Loss From Chemotherapy in Breast Cancer Patients | active not recruiting | N/A | 34 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT00903591 | Study of Radiation Exposure and Bilateral Breast Cancer | active not recruiting | — | 1,699 | Memorial Sloan Kettering Cancer CenterOTHER | 3 | Jun 3, 2026 | clinicaltrials |
| NCT01134172 | Ethnic Differences in the Impact of Breast Cancer on Employment Status, Financial Situation, and Quality of Life | active not recruiting | — | 935 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT02927912 | Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction | active not recruiting | Phase 2 | 108 | Ohio State University Comprehensive Cancer CenterOTHER | 2 | Jun 3, 2026 | clinicaltrials |
| NCT07624734 | Impact of the Intraoperative Use of Amines in Breast Cancer Surgery on Tumor Recurrence(MASTECTAMINE) | active not recruiting | — | 250 | University Hospital, MontpellierOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT03429907 | An Early Stress-Reduction Intervention in Patients With Newly Diagnosed Breast Cancer | active not recruiting | N/A | 62 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05056077 | Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)(TTBF) | active not recruiting | N/A | 353 | University of California, San FranciscoOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07619781 | Research on the Development and Validation of Personalized Exercise Prescriptions for Breast Cancer Patients Based on Large Language Models | active not recruiting | — | 220 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT02810743 | Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer(Subito) | active not recruiting | Phase 3 | 174 | The Netherlands Cancer InstituteOTHER | 2 | Jun 1, 2026 | clinicaltrials |
| NCT05720910 | Streamlined Geriatric and Oncological Evaluation Based On IC Technology(FRONE) | active not recruiting | N/A | 720 | Institut BergoniéOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05783622 | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies | active not recruiting | Phase 1 | 130 | Janux TherapeuticsINDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05203445 | A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer | active not recruiting | Phase 2 | 6 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT04514484 | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | active not recruiting | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT04568616 | Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)(NAOMI) | active not recruiting | Phase 2 | 178 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | May 28, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 17, 2026source: clinicaltrials